🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

126+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 20 of 126 recruiting trials for “b-lymphoblastic-leukemialymphoma-with-hyperdiploidy

RecruitingNCT07326930

Tracjectories and Predictors of Chemotherapy Induced Peripheral Neuropathy in Children With Acute Lymphoblastic Leukemia

👨‍⚕️ Ka Yan Ho, The Hong Kong Polytechnic University📍 3 sites📅 Started Jun 2025View details ↗
Phase 2, PHASE3RecruitingNCT07059156

Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL

🏥 Shanxi Bethune Hospital📍 1 site📅 Started Jun 2025View details ↗
Phase 4RecruitingNCT07016165

Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies

🏥 Gadjah Mada University📍 1 site📅 Started Jun 2025View details ↗
Phase 1, PHASE2RecruitingNCT06533579

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

👨‍⚕️ Vironexis Clinical Trials, Vironexis Biotherapeutics Inc.📍 9 sites📅 Started May 2025View details ↗
Phase 2RecruitingNCT06124157

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

👨‍⚕️ Thai Hoa Tran, Children's Oncology Group📍 139 sites📅 Started May 2025View details ↗
NARecruitingNCT06940960

JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia

👨‍⚕️ Jinqi Huang, PhD, Guangzhou First People's Hospital📍 1 site📅 Started May 2025View details ↗
Phase 2RecruitingNCT06847269

CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia

👨‍⚕️ Aimee Talleur, MD, St. Jude Children's Research Hospital📍 1 site📅 Started May 2025View details ↗
Phase 1RecruitingNCT06934382

Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma

👨‍⚕️ Caroline Diorio, MD, Children's Hospital of Philadelphia📍 1 site📅 Started Apr 2025View details ↗
Phase 2RecruitingNCT07012447

Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations

👨‍⚕️ Yue-jun Liu, The First Affiliated Hospital of Soochow University📍 1 site📅 Started Apr 2025View details ↗
Phase 1RecruitingNCT06879340

Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies

👨‍⚕️ Joseph McGuirk, D.O., University of Kansas Medical Center📍 1 site📅 Started Mar 2025View details ↗
Phase 2RecruitingNCT06559345

A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL

👨‍⚕️ Xiangbo Wan, PhD., The First Affiliated Hospital of Zhengzhou University📍 1 site📅 Started Mar 2025View details ↗
Phase 2, PHASE3RecruitingNCT06855810

Newly-diagnosed Pediatric T-cell ALL Protocol

👨‍⚕️ Xiaofan Zhu, MD, Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC📍 27 sites📅 Started Mar 2025View details ↗
Phase 2, PHASE3RecruitingNCT06882057

Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol

👨‍⚕️ Xiaofan Zhu, MD, Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC📍 27 sites📅 Started Mar 2025View details ↗
Phase 2RecruitingNCT06564545

A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Adult ALL

👨‍⚕️ Xiangbo Wan, PhD., The First Affiliated Hospital of Zhengzhou University📍 1 site📅 Started Mar 2025View details ↗
NARecruitingNCT06890065

JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia

🏥 Shenzhen Genocury Biotech Co., Ltd.📍 1 site📅 Started Mar 2025View details ↗
Phase 2RecruitingNCT06564493

A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL

🏥 The First Affiliated Hospital of Zhengzhou University📍 1 site📅 Started Mar 2025View details ↗
Phase 2RecruitingNCT06557161

A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Adult ALL

🏥 The First Affiliated Hospital of Zhengzhou University📍 1 site📅 Started Mar 2025View details ↗
Phase 1, PHASE2RecruitingNCT06481735

TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL

🏥 Chinese PLA General Hospital📍 6 sites📅 Started Feb 2025View details ↗
Phase 2RecruitingNCT06514794

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

👨‍⚕️ Cherry Thomas, MD, Wugen, Inc.📍 10 sites📅 Started Jan 2025View details ↗
Phase 2RecruitingNCT06390319

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

👨‍⚕️ Seth E. Karol, MD, MSCI, St. Jude Children's Research Hospital📍 3 sites📅 Started Dec 2024View details ↗
← PreviousPage 2 of 7Next →

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →